Hot Stocks

Hot stocks are not about hype. They emerge when powerful themes, policy shifts, and capital flows converge. InvestorPlace analysts track fast-moving market narratives, especially in technology, AI, and infrastructure, to identify stocks drawing outsized attention and explain what is really driving those moves.

Dell Dealing, Apple Reeling — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Dell surged Monday on news of a possible private equity deal, while Apple tumbled on reportedly low demand for iPhone 5s.

Should I Buy Research In Motion? 3 Pros, 3 Cons

By Tom Taulli, InvestorPlace Contributor
If your time horizon is short, RIM should do OK. But the longer term appears to be far more fraught with tough challenges.

Toyota Takes No. 1 Spot Back From GM

By Christopher Freeburn, InvestorPlace Writer
Toyota has regained the title of top-selling global carmaker, which is lost to GM in 2011.

AOL Still Needs to Patch Up Patch

By Jonathan Berr, InvestorPlace Contributor
CEO Tim Armstrong's hyperlocal news network isn't carrying its weight yet. And that's after some serious cost-cutting.

What Carl Icahn Could Mean for Transocean

By Alyssa Oursler, InvestorPlace Contributor
Today, Transocean revealed that Carl Icahn owns a 1.56% stake and is looking to grow that to over 3%. Is that good news for the oil-services firm?

Apple and iPhone Trouble: Either Sell Now or Hold for a Year

By Jeff Reeves
I remain convinced that Apple’s long-term potential is real based on its strong position in the tablet market and dividend growth.

A Doubled Dividend Doesn’t Make Ford a Must-Buy Now

By Susan J. Aluise, Aviation, Auto & Transportation Writer
Despite its hot streak, too many problems loom in the short term. Here are four reasons this isn't the right time to start a position in F.

Biotech Movers: Dendreon Pops, ArQule Drops

By Kyle Woodley, Senior Investing Editor, Kiplinger
An analyst upgrade on DNDN lifted the shares 21% last Friday, but mid-stage trial failure of a colorectal drug sank ARQL 11% the same day.

Lowe’s Brushes Downgrade Dirt off Its Shoulder

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader
While Canaccord Genuity's downgrade of Lowe's stock has some merit, citing its big run does not. LOW shares agree, and are already mounting a counter-run.

Petrobras: Great Reserves, Awful Stock

By Aaron Levitt, InvestorPlace Contributor
It's awash in oil and is on a roll in finding new monster fields offshore. But government interference is stifling its potential and keeping investors at bay.

5 Sectors for Big Profits as Earnings Season Begins

By Traders Reserve
Earnings season is rolling into high gear and here is an opportunity to profit in 5 sectors where earnings may be hard to come by for investors

Gold Gives Back Most of Thursday’s Gains

By Nate Wooley, InvestorPlace Writer
Precious metals gave back most of Thursday's gains today as predictions of a weakened U.S. GDP came out.

The Risky Business of Betting on the Box Office

By Lawrence Meyers, InvestorPlace Contributor
Popcorn company stocks are probably better investments than most movie exhibitors. There's no telling how many people will see a movie, so be selective.

S&P Hits Five-Year High — Thursday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor
Positive earnings news, big corporate headlines and solid China exports helped move markets north and launched the S&P to five-year highs.

Gold Rises Strongly on Draghi’s Remarks

By Nate Wooley, InvestorPlace Writer
Gold posted its biggest one-day gain of the year as ECB President Mario Draghi made positive remarks about Europe's economic outlook.

Lumia Lights Up Nokia Stock

By Tom Taulli, InvestorPlace Contributor
The Lumia might very well be the real deal -- or so Nokia's preliminary Q4 report would indicate. Could NOK really be a tech turnaround?

Hedge Funds Battling Over Herbalife? Run!

By Dan Burrows, InvestorPlace Feature Writer
Don't get caught between these titans as they do battle. On one side is Bill 'Pyramid Scheme' Ackman. On the other, Dan 'Buy It' Loeb. Oy.

Now That the Vivus Dust Has Settled …

By James Brumley, InvestorPlace Feature Writer
The diet-drug maker deserves a second -- more optimistic -- look after the hype and unmeetable expectations have passed.

Bad News for Yahoo Search Traffic and Mail

By Tom Taulli, InvestorPlace Contributor
Surprising declines in November and December could be mean problems for monetization.
Load More Articles